4th Quarter - Report

ERNST & YOUNG LLP (WASHINGTON COUNCIL ERNST & YOUNG) for CARIS SCIENCE, INC.

Period 4th Quarter 2016 Filed Jan 20, 2017 Signed by Amy Jensen Cunniffe

Official filing
Firm
ERNST & YOUNG LLP (WASHINGTON COUNCIL ERNST & YOUNG)
Client
CARIS SCIENCE, INC.
Income
$30,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Precision medicine policies. Appropriate regulatory oversight of diagnostic testing. Coverage and reimbursement of Next Generation Sequencing and other technologies. Cancer Moonshot. 21st Century Cures legislation (HR 6/HR 34)

Foreign entity interest: Caris Life Sciences, LTD, as the parent company, has an indirect interest in Caris Science Inc.

LobbyistCovered position, as disclosed
AMY JENSEN CUNNIFFE —

Contacted: White House Office; SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 34 (114th), H.R. 6 (114th)

Medicare/Medicaid MMM

Precision medicine policies. Appropriate regulatory oversight of diagnostic testing. Coverage and reimbursement of Next Generation Sequencing and other technologies. Cancer Moonshot. 21st Century Cures legislation (HR 6/HR 34)

Foreign entity interest: Caris Life Sciences, LTD, as the parent company, has an indirect interest in Caris Science Inc.

LobbyistCovered position, as disclosed
AMY JENSEN CUNNIFFE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; White House Office

Bills named: H.R. 34 (114th), H.R. 6 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.